Title:
PROTEIN BASED TNF-ALPHA VARIANTS FOR THE TREATMENT OF TNF-ALPHA RELATED DISORDERS
Document Type and Number:
WIPO Patent Application WO2005035564
Kind Code:
A3
Abstract:
The invention relates to novel proteins with TNF-alpha antagonist activity and nucleic acids encoding these proteins. The invention further relates to the use of the novel proteins in the treatment of TNF-alpha related disorders.
More Like This:
| WO/1991/001144 | LABELED POLYPEPTIDE DERIVATIVES |
| JPH0380082 | HUMAN LYMPHOTOXIN DERIVATIVE |
| JPS6430596 | NOVEL PHYSIOLOGICALLY ACTIVE POLYPEPTIDE |
Inventors:
DESJARLAIS JOHN R (US)
STEED PAUL MICHAEL (US)
ZALEVSKY JONATHAN (US)
SZYMKOWSKI DAVID EDMUND (US)
STEED PAUL MICHAEL (US)
ZALEVSKY JONATHAN (US)
SZYMKOWSKI DAVID EDMUND (US)
Application Number:
PCT/US2004/034880
Publication Date:
November 24, 2005
Filing Date:
October 12, 2004
Export Citation:
Assignee:
XENCOR INC (US)
DESJARLAIS JOHN R (US)
STEED PAUL MICHAEL (US)
ZALEVSKY JONATHAN (US)
SZYMKOWSKI DAVID EDMUND (US)
DESJARLAIS JOHN R (US)
STEED PAUL MICHAEL (US)
ZALEVSKY JONATHAN (US)
SZYMKOWSKI DAVID EDMUND (US)
International Classes:
C07K14/525; C07K14/705; (IPC1-7): C07K14/525
Domestic Patent References:
| WO2003033720A2 | 2003-04-24 |
Foreign References:
| US20030138401A1 | 2003-07-24 | |||
| US20020110868A1 | 2002-08-15 | |||
| US5597899A | 1997-01-28 |
Other References:
STEED PAUL M ET AL: "Inactivation of TNF signaling by rationally designed dominant-negative TNF variants.", SCIENCE (WASHINGTON D C), vol. 301, no. 5641, 26 September 2003 (2003-09-26), pages 1895 - 1898, XP002320440, ISSN: 0036-8075
Download PDF: